Stéfano Kim

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study

Stéfano Kim, Éric François, Thierry André et al. · The Lancet Oncology · 2018 · 140 citations

Gastrointestinal Oncology, Medicine, Metronomic Therapy +6

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial

Alice Bernard‐Tessier, Emmanuelle Jeannot, David Guenat et al. · Clinical Cancer Research · 2018 · 90 citations

Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer

Naomi Urano, Yoshiyuki Fujiwara, Yuichiro� Doki et al. · International Journal of Oncology · 2006 · 79 citations · Full text

Tumor Biology, Oncology, Class Iii Beta-tubulin +14

A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)

Sheela Rao, Gayathri Anandappa, Jaume Capdevila et al. · ESMO Open · 2022 · 69 citations · Full text

DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma

Stéfano Kim, Marine Jary, Luigi Mansi et al. · Annals of Oncology · 2013 · 54 citations · Full text

Promising Treatment, Gastrointestinal Oncology, Medicine +6